ecrin-mdr-crcClinical2021IPD Sharing (as of December 2022): No Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer’s data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.Ovarian CancerAnorexiaNon-small Cell Lung CancerColorectal CancerFatigueCachexiaProstate CancerWasting SyndromePancreatic CancerBreast CancerLoss of AppetiteOvarian CancerAnorexiaLoss Of AppetiteNon-small Cell Lung CancerColorectal CancerFatigueProstate CancerCachexiaPancreatic CancerWasting SyndromeBreast CancerInterventionalhttps://newmdr.ecrin.org/Study/2371114CanadaUnited States5Cancer, anorexia, cachexia, weight loss, loss of appetite, fatigueECRIN MDRCompletedfalseStudy to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and AnorexiaStudy to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite and to find out how participants with advanced cancer and anorexia feel after receiving repeated subcutaneous (SC-injected under the skin) doses.2021-05-152371114NCT04803305